PET/MRI Imaging of Glutamate Release in the Brain

University of Zurich (UZH)

Status and phase: Terminated; Phase 2

Conditions: Healthy

Treatments: Drug: 18F-PSS232

Study type: Interventional

Funder types: Other

Identifiers

NCT02511691

KEK ZH 2014-0441

Details and patient eligibility

About

Based on PET (18-PSS232) and MRI, glutamate release after N-acetylcystein challenge will be monitored in human brains.

Full description

Diagnostic trial with quantification of glutamate release in PET/MR.

Enrollment: 10 patients

Sex: All

Ages: 20 to 75 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• healthy volunteer

Exclusion criteria

• smoker
• drug addiction
• significant neurological or psychiatric conditions

Trial design

Primary purpose: Diagnostic

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

10 participants in 1 patient group

18F-PSS232

Other group

Description:

Subjects receive baseline PET with 18F-PSS232 and stimulation PET with 18F-PSS232 after medical challenge with N-acetylcystein

Treatment:

Drug: 18F-PSS232